CRIS : Summary for Curis, Inc. - Yahoo Finance

U.S. Markets open in 5 mins.

Curis, Inc. (CRIS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.880.00 (0.00%)
At close: 4:00PM EDT

2.88 0.00 (0.00%)
Pre-Market: 9:23AM EDT

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close2.88
Bid2.50 x 200
Ask2.99 x 1200
Day's Range2.82 - 2.92
52 Week Range1.47 - 3.72
Avg. Volume529,852
Market Cap408.64M
PE Ratio (TTM)-6.33
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube2 days ago

    ETFs with exposure to Curis, Inc. : March 27, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Curis, Inc. Here are 5 ETFs with the largest exposure to CRIS-US. Comparing the performance and risk of Curis, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Curis, Inc. :CRIS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
    Capital Cube9 days ago

    Curis, Inc. :CRIS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis Curis, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Curis, Inc. – Exelixis, Inc., Infinity Pharmaceuticals, Inc., Emergent BioSolutions Inc., Bristol-Myers Squibb Company, Spectrum Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Pfizer Inc. and Celgene Corporation (EXEL-US, INFI-US, EBS-US, BMY-US, ... Read more (Read more...)

  • GlobeNewswire13 days ago

    Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference

    LEXINGTON, Mass., March 16, 2017-- March 16, 2017- Curis, Inc., a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, ...